

Special Issue

Peptide-Based Vaccines against Infectious Diseases and Cancer

Message from the Guest Editors

Vaccination is one of the most successful tools for reducing the incidence of infectious diseases. Peptide-based subunit vaccines have emerged as promising prophylactic and therapeutic medication against several infectious diseases including group A streptococcus, malaria, TB, and cancer. Peptide-subunit-based vaccines contain only the minimal immunogenic region of an antigen necessary to elicit the desired immune response. Therefore, only safe and effective epitopes can be selected, removing the risk of allergic and autoimmune responses. However, peptides do not contain the danger signals that are needed to activate the immune system. Thus, an adjuvant/delivery system must be included to stimulate an immune response against the peptide antigen.

Guest Editors

Dr. Waleed Hussein

Dr. Rachel Stephenson

Dr. Mariusz Skwarczynski

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/99326

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).